The global cell and gene therapy third-party logistics market size was valued at USD 1.81 billion in 2025 and is predicted to ...

CGTxchange leverages the combined capabilities of the organizations in an unprecedented way to engage a broad array of potential partners and funders to efficiently identify, evaluate, finance, ...

Expected rapid advances in CAR T and other cellular therapies may expand treatment options not only in cancer but also in ...

GEN’s first virtual event of 2026—we present a group of outstanding researchers and thought-leaders to discuss the latest advances and challenges in delivering genetic therapies.

Despite a Trump administration push, there are few facilities offering the complex treatment in the rural areas where many ...

This article explores the US and EU compliance requirements to ensure patient safety for GMP ancillary materials in cell and ...

True patient-centricity will drive commercial success as CGT moves beyond first-generation therapies. Current timelines in CGT, from diagnosis to treatment, can exceed six months, often compounded by ...

In today’s Pharmaceutical Executive Daily, Amgen announces an $840 million acquisition of Dark Blue Therapeutics, GSK enters ...

Labroots and the Cell & Gene Therapy planning committee are thrilled to announce the 2nd Annual Cell & Gene Therapy Virtual Event Series, live on October 15, 2025. This free, interactive event brings ...

According to DataM Intelligence, the global cell and gene therapy market reached a value of US$13.90 billion in 2024 and is projected to ...

Abu Dhabi successfully completes its first gene therapy for genetic blood disorders, revolutionizing treatment approaches for ...

A preclinical study uncovered a new gene therapy that targets pain centers in the brain while eliminating the risk of ...